SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E (individually and in combination) on the incidence of prostate cancer as determined by routine clinical management. The accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men). Study duration will be twelve years with a five-year uniform accrual period. Participants will receive study supplements from the time of their randomization until the end of the trial period, between seven and twelve years depending upon when the participant was randomized.